Literature DB >> 15325597

Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program.

Maria Cristina Bronharo Tognim1, Soraya Sgambatti Andrade, Suzane Silbert, Ana Cristina Gales, Ronald N Jones, Hélio S Sader.   

Abstract

OBJECTIVES: To analyze the antimicrobial susceptibility of Acinetobacter spp. isolates collected from Latin American medical centers as part of the SENTRY Antimicrobial Surveillance Program and also to evaluate the dissemination of multi-drug resistant Acinetobacter spp. strains in the region.
METHODS: A total of 826 isolates of Acinetobacter spp. from multiple infection sites were collected from January 1997 to December 2001 in ten medical centers and susceptibility tested to >25 selected agents by broth microdilution. Multi-drug resistant Acinetobacter spp. isolates were molecular typed.
RESULTS: Resistance rates to carbapenems varied significantly among countries. A continued annual increase occurred in the Argentinean medical centers. In contrast, carbapenem resistance was rare in Chilean centers, and decreased significantly in the Brazilian institutions. Acinetobacter spp. isolates recovered from lower respiratory tract and bloodstream infections were associated with lower antimicrobial susceptibility rates. Resistance rates to imipenem were higher among isolates collected from intensive care units (13.5%) than among isolates from other units. A major ribogroup pattern (521-1) was detected among eight Acinetobacter spp. strains isolated from three distinct Latin American countries.
CONCLUSIONS: This study found that antimicrobial resistance is still a major issue among Acinetobacter spp. isolates collected from some Latin American countries. The dissemination of a major bacterial cluster in different regions reinforces the importance of longitudinal surveillance programs, such as SENTRY, as valuable tools for monitoring antimicrobial susceptibility rates and guiding local interventions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15325597     DOI: 10.1016/j.ijid.2003.11.009

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  27 in total

1.  The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.

Authors:  Thomas A Russo; Nicole R Luke; Janet M Beanan; Ruth Olson; Shauna L Sauberan; Ulrike MacDonald; L Wayne Schultz; Timothy C Umland; Anthony A Campagnari
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China.

Authors:  Ting Xu; Wenying Xia; Guodong Rong; Shiyang Pan; Peijun Huang; Bing Gu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 3.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 4.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

5.  In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii.

Authors:  Thomas A Russo; Malcolm G P Page; Janet M Beanan; Ruth Olson; Andrea M Hujer; Kristine M Hujer; Michael Jacobs; Saralee Bajaksouzian; Andrea Endimiani; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2011-02-13       Impact factor: 5.790

Review 6.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 7.  Acinetobacter infections: a growing threat for critically ill patients.

Authors:  M E Falagas; E A Karveli; I I Siempos; K Z Vardakas
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Nicole R Luke; Steven R Gill; Anthony A Campagnari
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

10.  Evolution of a pathogen: a comparative genomics analysis identifies a genetic pathway to pathogenesis in Acinetobacter.

Authors:  Jason W Sahl; John D Gillece; James M Schupp; Victor G Waddell; Elizabeth M Driebe; David M Engelthaler; Paul Keim
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.